Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ATM Q654Rfs*10 |
| Therapy | Talazoparib |
| Indication/Tumor Type | invasive bladder transitional cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM Q654Rfs*10 | invasive bladder transitional cell carcinoma | predicted - sensitive | Talazoparib | Case Reports/Case Series | Actionable | In a clinical case study, Talzenna (talazoparib) treatment resulted in a complete response in a patient with metastatic muscle-invasive urothelial carcinoma harboring ATM Q654Rfs*10 (reported as Q654fs*10), along with BRCA2 K3326* and CHEK2 R145Q (PMID: 38638285). | 38638285 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38638285) | Personalized treatment with PARP inhibitors in advanced urothelial carcinoma: a case report and literature review. | Full reference... |